Flerie Invest to acquire Cobra Biologics from Charles River for $52m.

Flerie Invest, a venture capital firm, agreed to acquire Cobra Biologics, a provider of pharmaceutical and biotechnology research services, from Charles River, a pharmaceutical company, for $52m. “I look forward to working with the highly competent staff in Matfors to help grow innovative biotech companies, and to create security of supply of drugs and vaccines, and so be better prepared for future pandemics,” Ted Fjällman, Flerie Invest Partner.